DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Baselga J, Faye Dent S, Cortés J. et al.
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients
(pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally
advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
J Clin Oncol. 2018
36. (18_suppl)
We do not assume any responsibility for the contents of the web pages of other providers.